Author

A. McCormick

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

A. Califano· 1 shared A. Hawarden· 1 shared A. Sura· 1 shared B. Russell· 1 shared B. Whalley· 1 shared C. Kuo· 1 shared C. Rada· 1 shared C. Roberts· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPhysiology

A. Califano

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Therapeutic modulation of the blood-brain barrier and ischemic stroke by a bioengineered FZD4-selective WNT surrogate

J. Ding, S.-J. Lee, L. Vlahos, K. Yuki, C. Rada, V. van Unen, M. Vuppalapaty, H. Chen, A. Sura, A. McCormick, M. Tomaske, S. Alwahabi, H. Nguyen, W. Nowatzke, L. Kim, , C. Kuo

This study develops a bioengineered FZD4-selective WNT surrogate that improves BBB function and reduces ischemic stroke damage in mice.

bioRxiv · Oct 13, 2022 · PreprintPhysiology

The heterogeneity of the DNA damage response landscape determines patient outcomes in ovarian cancer

T. Walker, Z. Faraahi, m. price, A. Hawarden, C. Waddell, B. Russell, D. Jones, A. McCormick, N. Gavrielides, S. Tyagi, L. Woodhouse, B. Whalley, C. Roberts, E. Crosbie, R. Edmondson

The paper shows that DDR heterogeneity in ovarian cancer predicts patient outcomes and chemotherapy response by analyzing DDR pathway interactions and constructing predictive DDR signatures.

bioRxiv · Aug 3, 2021 · PreprintCell Biology